EXHIBIT 4.2 THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD,...Stem Cell Innovations, Inc. • November 22nd, 2006 • Biological products, (no disgnostic substances) • New York
Exhibit 10.56 SUBSCRIPTION AGREEMENT Interferon Sciences, Inc. 783 Jersey Avenue New Brunswick, New Jersey 08901 Attn.: Chief Executive Officer Gentlemen: 1. Subscription. The undersigned is hereby purchasing from Interferon Sciences, Inc., a Delaware...Subscription Agreement • April 15th, 1998 • Interferon Sciences Inc • Biological products, (no disgnostic substances) • New York
Exhibit 10.4 FORM OF GUARANTY ---------------- 1. Identification. -------------- This Guaranty (the "Guaranty"), dated as of November16, 2006, is entered into by Stem Cell Innovations BV, a Netherlands corporation, Amphioxus Cell Technologies, Inc., a...Stem Cell Innovations, Inc. • November 22nd, 2006 • Biological products, (no disgnostic substances) • New York
Exhibit 10.59 EMPLOYMENT AGREEMENT AGREEMENT, dated as of October 1, 1997, between Interferon Sciences, Inc., a Delaware corporation with principal executive offices at 783 Jersey Avenue, New Brunswick, New Jersey 08901 (the "Company"), and Lawrence...Employment Agreement • April 15th, 1998 • Interferon Sciences Inc • Biological products, (no disgnostic substances) • New Jersey
ARTICLE IStem Cell Innovations, Inc. • November 22nd, 2006 • Biological products, (no disgnostic substances) • New York
Exhibit 10.2 SECURITY AGREEMENT ------------------ 1. Identification. -------------- This Security Agreement (the "Agreement"), dated as of November 16, 2006, is entered into by and between Stem Cell Innovations, Inc., a Delaware corporation...Security Agreement • November 22nd, 2006 • Stem Cell Innovations, Inc. • Biological products, (no disgnostic substances) • New York
EXHIBIT 2.2 AGREEMENT made as of March 11, 2003 by, and between Interferon Sciences, Inc. ("Seller"), and Hemispherx Biopharma, Inc. ("Buyer"). WITNESSETH: In consideration of the mutual covenants, agreements, representations and warranties herein...Agreement • March 18th, 2003 • Interferon Sciences Inc • Biological products, (no disgnostic substances) • Delaware
EXHIBIT 10.1 SUBSCRIPTION AGREEMENT ---------------------- THIS SUBSCRIPTION AGREEMENT (this "Agreement"), dated as of November 16, 2006, by and among Stem Cell Innovations, Inc. (formerly known as Interferon Sciences, Inc.), a Delaware corporation...Subscription Agreement • November 22nd, 2006 • Stem Cell Innovations, Inc. • Biological products, (no disgnostic substances) • New York
Exhibit 10.3 COLLATERAL AGENT AGREEMENT -------------------------- COLLATERAL AGENT AGREEMENT (this "Agreement") dated as of November 16, 2006, among Barbara R. Mittman (the "Collateral Agent"), and the parties identified on Schedule A hereto (each,...Collateral Agent Agreement • November 22nd, 2006 • Stem Cell Innovations, Inc. • Biological products, (no disgnostic substances) • New York
EXHIBIT 2.1 AGREEMENT made as of March 11, 2003 by, and between Interferon Sciences, Inc. ("Seller"), and Hemispherx Biopharma, Inc. ("Buyer"). WITNESSETH: In consideration of the mutual covenants, agreements, representations and warranties herein...Agreement • March 18th, 2003 • Interferon Sciences Inc • Biological products, (no disgnostic substances) • Delaware
MODIFICATION AGREEMENTModification Agreement • January 7th, 2009 • Stem Cell Innovations, Inc. • Biological products, (no disgnostic substances) • New York
This Modification Agreement (“Agreement”) dated as of December , 2008 is entered into by and among Stem Cell Innovations Inc., a Delaware corporation (the “Company”), the noteholders identified on the signature page hereto (each a “Lender” and collectively “Lenders”) and Alpha Capital Anstalt as “Lender” and as a secured Lender (“Alpha”).
EXHIBIT 10.55 *Certain information omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2(b). ----------------------------------------------------------------- INTEGRATED ACCESS CENTER SERVICES AGREEMENT This...Access Center Services Agreement • August 14th, 1997 • Interferon Sciences Inc • Biological products, (no disgnostic substances) • California
Exhibit 10.1 Date: February 21, 2007 To: STEM CELL INNOVATIONS, INC. 1812 FRONT STREET SCOTCH PLAINS NJ 07076 908-663-2150 By fax and email Attention: Mark Germain Re: Equity investment and license agreement ---------------------------------------...Stem Cell Innovations, Inc. • February 27th, 2007 • Biological products, (no disgnostic substances)
EXHIBIT 10.54 *Certain information omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2(b). ------------------------------------------------------------------------ Agreement, dated as of April 1, 1997,...Agreement • August 14th, 1997 • Interferon Sciences Inc • Biological products, (no disgnostic substances)
Exhibt 10.58 EMPLOYMENT AGREEMENT AGREEMENT, dated as of _________, 1997, between Interferon Sciences, Inc., a Delaware corporation with principal executive offices at 783 Jersey Avenue, New Brunswick, New Jersey 08901 (the "Company"), and...Employment Agreement • April 15th, 1998 • Interferon Sciences Inc • Biological products, (no disgnostic substances) • New Jersey
Interferon Sciences, Inc. 783 Jersey Avenue New Brunswick, NJ 08901 January 1, 1996 National Patent Development Corporation 9 West 57th Street Suite 4170 New York, NY 10019 Gentlemen: Interferon Sciences, Inc. ("ISI") and National Patent Development...Interferon Sciences Inc • March 22nd, 1996 • Biological products, (no disgnostic substances)
Interferon Sciences, Inc. ("ISI") and National Patent Development Corporation ("NPDC") are party to a Management Services Agreement dated January 1, 1981 (the "Agreement"). The Agreement provides, among other things, that:
SECURED NOTEStem Cell Innovations, Inc. • January 7th, 2009 • Biological products, (no disgnostic substances) • New York
This Note has been entered into pursuant to the terms of a subscription agreement between the Borrower and the Holder of promissory notes dated of even date herewith (the “Subscription Agreement”). Unless otherwise separately defined herein, all capitalized terms used in this Note shall have the same meaning as is set forth in the Subscription Agreement. The following terms shall apply to this Note:
SECOND MODIFICATION AGREEMENTSecond Modification Agreement • June 4th, 2009 • Stem Cell Innovations, Inc. • Biological products, (no disgnostic substances) • New York
This Second Modification Agreement (“Agreement”), dated as of May 29, 2009 is entered into by and among Stem Cell Innovations, Inc., a Delaware corporation (the “Company”), Margie Chassman (“Chassman”) and Alpha Capital Anstalt (“Alpha”).
SUBSCRIPTION AGREEMENTSubscription Agreement • January 7th, 2009 • Stem Cell Innovations, Inc. • Biological products, (no disgnostic substances) • New York
THIS SUBSCRIPTION AGREEMENT (this “Agreement”), is dated as of December , 2008, by and among Stem Cell Innovations, Inc., a Delaware corporation (the “Company”), and Alpha Capital Anstalt (“Subscriber”).
